GOG Resources Available to Support Basic and Translational Research


The GOG has resources to facilitate the research goals of basic and translational investigators who are planning to submit or presently hold independently funded grants (i.e., RO1, R21, PPG, DOD, etc.).   Investigators are encouraged to contact the GOG early in their grant planning process to discuss their research ideas and to determine the feasibility of utilizing GOG resources for their research proposals.  The following lists GOG resources that may be of value for your planned research.

 GOG Protocol Development Committee

The GOG Protocol Development Committee has the ultimate responsibility for the strategic direction and development of all clinical trials conducted within the group. The chair and co-chair and their contact information for this committee are listed below.

Protocol Development Committee: Chair Robert S. Mannel [Robert_Mannel@ouhsc.edu], Co-chair: Ronald D. Alvarez [rdalvarez@uab.edu]

GOG Disease Site Oriented Committees

The GOG disease site oriented committees are made up of multidisciplinary members; their goal is to develop and conduct well-designed phase III randomized trials for the major gynecologic cancers or definitive phase II trials for rare gynecologic cancers. The major GOG disease site committees and their respective chairs and co-chairs and contact information are listed below.

Ovarian Committee: Chair: Michael A. Bookman [mbookman@azcc.arizona.edu], Co-chair: Paul A. DiSilvestro [pdisilvestro@wihri.org]

Uterine Corpus Committee: Chair: David S. Miller [david.miller@utsouthwestern.edu] Co-chair: Marcus Randall [merand2@email.uky.edu]

Cervix/Vulva Committee: Chair: Bradley J. Monk [bradly.monk@chw.edu] Co-chair: Wui Jin-Koh:[wkoh@u.washington.edu]

Rare Tumor Committee:  Chair: David Gershenson [dgershen@mdanderson.org], Al Covens [al.covens@sunnybrook.ca]

GOG Special Committees

Two GOG special committees of interest to potential investigators are the Developmental Therapeutics and the Experimental Medicine Committees.  The Developmental Committee fosters the early phase study of new drugs and innova­tive, combined-modality regimens, which might form the basis for future phase III trials.  The Experimental Committee is responsible for the coordination of translational research within both early phase and phase III trials conducted within the GOG.  The respective chairs and co-chairs and their contact information for these committees are listed below.

Developmental Therapeutics Committee:. Chair: Carol Aghajanian   [aghajanc@mskcc.edu]

Experimental Medicine Committee: Chair: Michael J. Birrer [mbirrer@partners.org], Co-chairs: William Beck [wtbeck@uic.edu] and Thomas Hamilton [tc_hamilton@fccc.edu]

The GOG Tissue Bank and Core Labs

The GOG has an extensive Tissue Bank and several other resources of potential use to basic and translational investigators.  A description of these resources and contact information is listed below.  

 The GOG Tissue Bank: (http://www.nationwidechildrens.org/biopathology-center-collaborations) has been funded and managed as a direct subcontract with the GOG since 1991 and is housed at the Biopathology Center (BPC), part of The Research Institute at Nationwide Children's Hospital (formerly Columbus Children's Research Institute) in Columbus, Ohio.  Currently, the BPC is federally funded to serve several clients (including the Pediatric Division of the Cooperative Human Tissue Network [pCHTN], and the biobanking efforts of the GOG, the Children's Oncology Group [COG], the Childhood Cancer Survivor Study [CCSS], the Cancer Therapy Evaluation Program [CTEP], and the Cancer Genome Atlas Project [TCGA]). Dr. Nilsa C. Ramirez [nilsa.ramirez@nationwidechildrens.org] serves as the PI and Medical Director.  Laura Monovich [laura.monovich@nationwidechildrens.org] is the Manager of the GOG Tissue Bank, and Rosa Huff is the Grants Administrator [rosa.huff@nationwidechildrens.org].

The purpose of the Bank is to support human specimen banking and provide the required infrastructure, procedures, and performance needed to ensure the collection, storage, and access to high-quality, well-annotated human specimens collected from NCI funded clinical trials.  The GOG Tissue Bank is focused on the long-term acquisition and storage of human tissues, cells, blood products and fluids to support and facilitate gynecologic cancer research, the management of specimens from patients enrolled in NCI-sponsored clinical trials, and to support approved protocols and projects with specimen requirements and/or either basic science or translational research objectives. Over 180,000 specimens have been banked thus far including fixed and frozen tumor tissue, fixed and frozen normal tissues, whole blood, sera, plasma, urine, and cells.  The following are available  for your consideration at this link:  


Bank Applications

Cooperative Group Banks (CGB) Biospecimen Access Applications

CGB Sample LOI for Access to Specimens

CGB Material Use Agreement


Clinical Pharmacology Core Laboratory: This facility provides state of the art pharmacokinetic and pharmacodynamic analyses and is housed in the Clinical Pharmacology Analytical Facility Core at the University of Pittsburgh Cancer Institute. Director: Jan Beumer [beumerjh@upmc.edu]

Hormone Receptor Core Laboratory: This lab provides a full range of techniques including immunohistochemical staining, real time PCR, and hormone receptor analyses.  Director: Kimberly Leslie [kimberly-leslie@uiowa.edu]

GOG Statistical and Data Center

The SDC will interact on investigations/grants, which have been approved previously for development by the Protocol Development Committee. Investigators are strongly encouraged to interact with the appropriate GOG disease site and/or GOG special committees early in the grant development process to ensure feasibility of utilizing GOG resources for their proposed research initiatives.  Interaction with the GOG SDC to review sample size and planned statistical evaluation is also strongly encouraged.  The contact person for statistical issues regarding translational research interactions is Mark Brady [mbrady@gogstats.org].  Dr. Brady will assign translational research/biostatistical collaborators within the SDC.  For planned grant applications, a budget for SDC support is required and a complete proposal must be submitted to the SDC eight weeks before the grant deadline to assess workload and develop the budget.  The contact person for the required grants/fiscal interaction is Sally Bialy [sbialy@gogstats.org].